Skip to main content
Premium Trial:

Request an Annual Quote

IP Roundup: Sep 29, 2009


Rosetta Genomics of Rehovot, Israel, has received US Patent No. 7,592,441, "Liver cancer-related nucleic acids." The patent claims microRNAs, miRNA precursors, and associated nucleic acids that can be used for diagnosis, prognosis, and treatment of liver cancer. Also described are methods that can be used to identify modulators of the disease-associated polynucleotides. Methods and compositions for linear amplification and labeling of a targeted nucleic acid are also provided. The amplified targeted molecules can be used in hybridization techniques like Luminex and microarray analysis, according to the patent inventors.

Hitachi has received US Patent 7,595,155, "Multiplex detection probes." The patent describes detection probes that use soluble bodies to retain multiple mass tag molecules. The detection probes may be used to assay different biological samples, each comprising analytes, by: a) immobilizing the analytes from each of the samples on a surface incubating the surface with a set of the detection probes, each having mass tag molecules with different masses; b) removing the unbound detection probe; c) collecting the first and second mass tag molecules from the bound detection probe; and d) quantifying the first and second mass tag molecules collected.

Biocept of San Diego has received US Patent No. 7,595,157, "Microarrays utilizing hydrogels." The patent claims a method of making a microarray by coating a flat substrate with a polymerizable hydrogel layer that contains anchoring moieties. Following curing, a continuous layer of uniform thickness is securely attached to the upper surface of the substrate through an array region. Probes are then attached to create microspots at distinct spatial locations on the surface of this slab layer by linking the probes to the anchoring moieties in the cured hydrogel. Such anchoring moieties may employ linking systems such as organic chelators, that are activated by copper or some other metal, and complementary pairs such as avidin-biotin, according to the patent.

Brigham and Women's Hospital of Boston has received US Patent No. 7,595,159, "Prediction of Parkinson's disease using gene expression levels of peripheral blood samples." The patent identifies a number of gene markers whose expression is altered in neurodegenerative diseases. The markers can be used to diagnose or predict ND in subjects, and can be used in the monitoring of therapies. In addition, the genes identify therapeutic targets, the modification of which may prevent ND development or progression, according to the patent.

Tufts University of Medford, Mass., has received US Patent No. 7,595,473, "Method and system of array imaging." The patent claims a method and system of array imaging that extends the longevity of the sensor array by minimizing the effects of photobleaching. According to the patent, the imaging system has a light source, a variable exposure aperture, and a variable filter system. The system extends the longevity of sensors by: a) using the variable exposure aperture to selectively expose sections of the sensor array containing representative numbers of each type of sensor; and b) using the variable filter system to control the intensity of the excitation light, providing only the intensity required to induce the appropriate excitation and increasing that intensity over time as necessary to counteract the effects of photobleaching.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.